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Inﬂammatory bowel diseases (IBDs) comprising Crohn disease (CD) and ulcerative colitis (UC) are chronic inﬂammatory
conditions with polygenic susceptibility. Interactions between TNF-alpha and TNF-alpha receptor play a fundamental role in
inﬂammatory response. This study investigates the role that selected single nucleotide polymorphisms (SNPs) and haplotypes
in the TNF-alpha receptor (TNSFRSF1B) gene play in the risk of IBD in a New Zealand Caucasian population. DNA samples
from 388CD, 405UC, 27 indeterminate colitis patients, and 293 randomly selected controls, from Canterbury, New Zealand were
screened for 3 common SNPs in TNSFRSF1B: rs1061622 (c.676T > C), rs1061624 (c.∗1663A > G), and rs3397 (c.∗1690T > C),
using TaqMan technologies. Carrying the rs1061624 variant decreased the risk of UC in the left colon (OR 0.73, 95%CI = 0.54–
1.00) and of being a smoker at diagnosis (OR 0.62; 95%CI = 0.40–0.96). Carrying the rs3397 variant decreased the risk of
penetrating CD (OR 0.62, 95%CI = 0.40–0.95). Three marker haplotype analyses revealed highly signiﬁcant diﬀerences between
CD patients and control subjects (χ2 = 29.9, df = 7, P = .0001) and UC cases and controls (χ2 = 46.3, df = 7, P<.0001). We
conclude that carrying a 3-marker haplotype in the TNSFRSF1B gene may increase (e.g., haplotype of GGC was 2.9-fold more
in the CD or UCpatients) or decrease (e.g., TGT was 0.47-fold less in UC patients) the risk of IBD in a New Zealand Caucasian
population.
Copyright © 2009 Lynnette R. Ferguson et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Inﬂammatory bowel diseases (IBDs), including Crohn dis-
ease (CD) and ulcerative colitis (UC), provide a good
example of a disorder for which there is compelling evidence
for genetically determined susceptibility that interacts with
environmental factors, including microbiota and diet [1]. It
is clear that there are strong ethnic diﬀerences in IBD sus-
ceptibility, and that diﬀerent populations may have varying
levels of genetic involvement, with distinctive risk alleles [2].
For example, although there is a very low incidence of CD
in Bangladesh, the children of Bangladesh immigrants to the
UK show a very high incidence of the disease [2]. As recently
as 2005, it seemed that a maximum of 10–12 genetic loci
could be involved in disease susceptibility [3], but whole
genome association studies have changed the landscape such
that a more recent meta-analysis [4] suggested involvement
of more than 30 diﬀerent loci. It becomes important to
establish which loci are relevant to individual population
groups living in speciﬁc locations.2 Gastroenterology Research and Practice
Table 1: TNFRSF1B polymorphisms tested in the Canterbury population.
rs number Location Nucleotide change Amino acid
position
Major allele
in Europeans
Frequency in other European
groups
rs.1061622 Exon 6 (nonsynonymous) c.676T > G 196 T 75% [Hapmap] 80.2% [Wachke]
rs.1061624 Exon 10 3
 UTR c.∗1663A > G A 51.7% [Hapmap] 55.2% [Washke]
rs.3397 Exon 10 3
 UTR c.∗1690T > C T 52.6% [Hapmap]
The prevalence and incidence of IBD in New Zealand
are believed to have increased substantially in recent years,
although stringently collated data are not available prior
to 2004 [5]. As at 1 June 2005, Gearry et al. (2006)
reported a prevalence of IBD in Canterbury, New Zealand,
as 308.3 per 100000 subjects (155.2 with CD and 145 with
UC per 100000). Although we have previously associated
polymorphisms in several genes including NOD1&2, TLR4,
DLG5,ATG16L1,andIL23RwithriskofIBDinNewZealand
[6–12], these only increase the IBD risk to a small extent and
cannot explain the high New Zealand disease incidence. For
example, carrying the common NOD2 1007-femtdsecond
mutation increased the risk of CD 4.4 fold (95% conﬁdence
interval 1.6–12) [12].
Tumor necrosis factor-alpha (TNF-α) is a proinﬂamma-
tory cytokine that plays a central role in IBD pathogenesis
[8]. An inhibitor of TNF-α, inﬂiximab (IFB), is an eﬀective
treatment of moderate to severe IBD, and polymorphisms
in the TNF-α gene not only aﬀect the phenotype of IBD,
but may also impact IFB susceptibility [8, 13]. However,
TNF-α does not work independently in the cell, but acts
through binding to two receptors, TNF receptor superfamily,
member 1A (TNFRSF1A or p55/p60) and TNF receptor
superfamily, member 1B (TNFRSF1B, also called TNFR,
p75/p80). TNFRSF1B is the larger of these receptors, being
present on many cell types, and strongly expressed on
stimulated T and B lymphocytes [14]. There is evidence
that it regulates the binding of TNF-α to TNFRSF1A, and
thus may regulate the levels of TNF-α necessary to stimulate
the action of the transcription factor, nuclear factor-kappa
B (NF-kB) [15]. The gene for TNFRSF1B is located on
chromosome 1p36.3-p36.2 [16–18], which coincides with
the previously identiﬁed IBD susceptibility locus, IBD7
[19].
Single nucleotide polymorphisms (SNPs) in TNFRSF1B
have been suggested to modulate the risk of a number
of autoimmune diseases, including rheumatoid arthritis,
systemic lupus erythematosus, and CD [20–24]. This study
considers the role of three SNPs in TNFRSF1B Table 1 on the
overallriskorphenotypeofIBDinaNewZealandCaucasian
population, recruited from the Canterbury region in New
Zealand [5] 2006. These SNPs were previously associated
with CD risk in other populations [22, 23].
2.MaterialsandMethods
2.1. Study Participants. T h ec a s e si nt h i ss t u d ya r ear a n -
dom subset of the Caucasian participants of the Canter-
bury Inﬂammatory Bowel Disease Project, which has been
described in detail elsewhere [5]. All subjects consented
to collection of peripheral blood for DNA extraction and
genotyping. Phenotypic characteristics of this cohort are
described in more detail by Tarrant et al. [25]. The database
included their clinical diagnosis and IBD phenotype as
deﬁned using standard diagnostic criteria and using the
Montreal Classiﬁcation system [26]. The Montreal classiﬁ-
cation was current as of 1 June 2005.
388 CD participants, 403 UC participants, and 27
indeterminate colitis (IC) participants were genotyped for
t h i ss t u d y ,a sd e s c r i b e di nTable 2. All participants self-
reported European ancestry, and patients who self-reported
having any Maori or other non-Caucasian ancestry are not
included.
The New Zealand Caucasian controls (n = 293) were
selected at random from the electoral roll, comprising 93%
of the population over eighteen years of age in Canterbury,
New Zealand [27].
2.2. Applied Biosystems TaqMan SNP Genotyping Assay.
SNPs were genotyped using the TaqMan MGB diallelic
discrimination system. Probes and oligonucleotides were
obtained from Applied Biosystems using the Assay-by-
Design product (listed in Table 3). For the marker c.676T
> C (rs1061622) a predesigned SNP genotyping assay was
available (C 8861232 20). The reactions were prepared by
using 2x TaqMan Universal Master Mix, 40x SNP Genotyp-
ing Assay Mix, DNase-free water, 10ng genomic DNA in a
ﬁnal volume of 5uL per reaction. The PCR ampliﬁcation
was performed using the ABI Prism 7900HT sequence-
detectormachineunderthefollowingconditions:10minutes
95◦C enzyme activation followed by 40 cycles at 92◦Cf o r
15 seconds and 60◦C for 1 minute (annealing/extension).
The allelic discrimination results were determined after the
ampliﬁcation by performing an endpoint read. To estimate
genotype accuracy approximately 5% of the samples, that
is, 70 cases were genotyped in duplicate or triplicate for
each of the markers. No conﬂicted duplicate genotypes were
detected.
2.2.1. Statistical Analysis. The allelic trend test [26]a n d
Fisher’s exact genotypic test were used to compare case and
control allele frequencies. An exact test was used to test for
departures from Hardy-Weinberg equilibrium (HWE) in the
case and the control samples [27]. Allelic odds ratios were
calculated and conﬁdence intervals for the allelic odds ratio
were also calculated under the assumption of HWE in the
cases and the control groups. Logistic regression analysis
was used to examine the relationship between genotypesGastroenterology Research and Practice 3
Table 2: Summary of clinical and demographic data for the set of Caucasian IBD patients.
CD n (%) UC n (%) IC n (%)
Gender
Female 249 (64.2) 214 (52.8) 15 (55.6)
Male 139 (35.8) 191 (47.2) 12 (44.4)
Age at ﬁrst diagnosis
Below 17 39 (10.0) 26 (6.4) 0
Between 17 and 40 199 (51.3) 184 (45.4) 15 (55.6)
Above 40 150 (38.7) 195 (48.2) 12 (44.4)
CD location
Ileal 125 (32.2)
Colonic 169 (43.6)
Ileocolonic 90 (23.2)
Unknown (U + UN) 4 (1.0)
UC location
Proctitis 140 (34.6) 3 (11.1)
Left colon 107 (26.4) 5 (18.5)
Pancolitis 154 (38.0) 19 (70.4)
Unknown 4 (1.0) 0
Behaviour
Nonstricturing, nonpenetrating perianal disease: With 47 (21.5)
Without 172 (78.5)
Stricturing perianal disease: With 46 (38.0)
Without 75 (62.0)
Penetrating perianal disease: With 17 (35.4)
Without 31 (64.6)
Any relative with IBD: Yes (n = 143) 74 (19.1) 65 (16.1) 5 (18.5)
Bowel resection: Yes (n = 214) 142 (36.6) 70 (17.3) 2 (7.4)
Smoker at diagnosis: Yes (n = 147) 97 (25.7) 49 (12.3) 2 (7.7)
Ever used immunomodulators: Yes (n = 296) 203 (52.3) 86 (21.2) 8 (29.6)
Extraintestinal manifestations: Yes (n = 142) 75 (19.3) 64 (15.8) 3 (11.1)
Table 3: Primer and probe sequences for custom-made TaqMan SNP genotyping assay for TNFRSF1B.
TaqMan SNP genotyping assay DNA sequence
TNFRSF1B ∗1663A > G forward primer 5
  TGACCTGCAGGCCAAGAG 3
 
TNFRSF1B ∗1663A > G reverse primer 5
  CCATGGCAGCAGAGGCTTT 3
 
TNFRSF1B ∗1663A > G VIC probe 5
  CCACAACTCGCTGCC 3
 
TNFRSF1B ∗1663A > G FAM probe 5
  CACAACCCGCTGCC 3
 
TNFRSF1B ∗1690T > C forward primer 5
  TGACCTGCAGGCCAAGAG 3
 
TNFRSF1B ∗1690T > C reverse primer 5
  CCATGGCAGCAGAGGCTTT 3
 
TNFRSF1B ∗1690T > C VIC probe 5
  CATGGCGTGTCCC 3
 
TNFRSF1B ∗1690T > C FAM probe 5
  CCATGGTGTGTCCC 3
 
and disease of CD, UC, and IBD using SAS (V9.1 SAS
Institute., Cary, NC, USA). Haplotype analysis was carried
out using haplo.stats in R [28] to test associations between
haplotypes and traits. We also performed an exploratory
analysis of allele frequency diﬀerences between controls and
patient subgroups using the clinical characteristics given in
Table 2.
3. Results
No signiﬁcant deviation from Hardy-Weinberg Equilibrium
wasfoundinthecontrolgroupforallthreeSNPs.Foreachof
the polymorphisms studied, the risks of carrying the variant
wascomparedCDandUCpatientswiththecontrolgroup,as
shown in Tables 4 and 5. There was no signiﬁcant diﬀerence4 Gastroenterology Research and Practice
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Table 6: Haplotype analysis of three-SNP TNFRSF1B haplotype in IBD status in New Zealand IBD patients and Caucasians.
Haplotype Case frequency Control frequency Hap frequency Hap-score P-value Global score
statistics
CD Three SNPs TNFRSF1B region
(rs1061622, rs1061624, rs3397)
GAC 0.057 0.101 0.075 −1.55 .12
χ2 = 29.9,
df = 7,
P = .0001
GAT 0.048 0.050 0.051 0.09 .93
GGC 0.091 0.031 0.064 2.78 .005
GGT 0.039 0.033 0.036 0.77 .44
TAC 0.210 0.277 0.241 −1.88 .06
TAT 0.172 0.064 0.122 3.29 .001
TGC 0.238 0.209 0.224 0.16 .88
TGT 0.145 0.236 0.186 −1.90 .06
UC Three SNPs TNFRSF1B region
(rs1061622, rs1061624, rs3397)
GAC 0.067 0.101 0.078 −0.92 .36
χ2 = 46.3,
df = 7,
P < .0001
GAT 0.057 0.050 0.056 0.43 .67
GGC 0.091 0.031 0.067 3.32 <.0001
GGT 0.036 0.033 0.034 0.63 .53
TAC 0.179 0.277 0.278 −2.81 .005
TAT 0.170 0.064 0.128 2.76 .006
TGC 0.289 0.209 0.259 1.75 .08
TGT 0.112 0.236 0.159 −3.40 .0007
in the allele frequencies of the TNFRSF1B rs1061622,
rs1061624, and rs3397 variants between CD or UC patients
and healthy control subjects.
Individuals carrying the rs1061622 variant showed no
signiﬁcantdiﬀerencesfromthosecarryingthereferenceallele
(the G allele), for overall risk of IBD or for any phenotypic
class. No signiﬁcant diﬀerences found any of the age at ﬁrst
diagnosis, any location of CD and UC, or CD behavior.
Having any relatives with IBD, bowel resection, smoke at
diagnosis, ever used immunomodulators, or any EIMs were
not signiﬁcanty diﬀerent between CD or UC patients and
controls.
For the rs1061624 variant, those individuals carrying the
AallelehadadecreasedprobabilityofdevelopingUClocated
in the left colon (OR = 0.73, 95% CI = 0.54–1.00, P = .05).
Carrying the A allele also reduced the probability of UC
patients having smoked at diagnosis (OR = 0.62, 95% CI
= 0.40–0.96, P = .03) but showed no statistically signiﬁcant
eﬀects in patterns of CD disease risk.
ThoseindividualscarryingthevariantTNFRSF1Brs3397
C allele showed a statistically signiﬁcant reduction in the
probability of developing CD with penetrating behavior, as
compared with those carrying the T allele (OR = 0.62, 95%
CI = 0.40–0.95, P = .03). No other phenotypes showed
signiﬁcant eﬀects in patterns of disease risk of CD. For UC
patients, those individuals carrying the variant rs3397 C
allele showed no statistically signiﬁcant eﬀects in patterns of
IBD (Table 4).
3.1. Haplotype Analysis. Table 6 summarizes the results of
haplotype analysis of the three TNFRSF1B SNPs (rs1061622,
rs1061624, and rs3397). Haplotype frequencies were esti-
mated, and association analyses were performed with respect
to CD and UC in New Zealand IBD patients and Caucasian
controls. A score for each haplotype (Hap-score) was calcu-
lated and P-value also calculated for the signiﬁcance of each
Hap-score. A positive hap-score implies that the haplotype
occurs more frequently in the CD or UC case group than
controlsubjects.AglobalP-valueteststheoverallassociation
between haplotypes and the response.
There was a signiﬁcant diﬀerence between these haplo-
types for CD patients and control subjects (χ2 = 29.9, df
= 7, P = .0001). In the three SNPs (rs1061622, rs1061624,
and rs3397) in CD, the frequencies of haplotypes of GGC
(9.1% for case versus 3.1% for control group, P = .005)
and TAT (17.2% versus 6.4%, P = .001) were signiﬁcantly
diﬀerent, with haplotypes GGC and TAT occurring more
in CD cases than the control group. TAC (21.0% versus
27.7%, P = .06) and TGT (14.5% versus 23.6%, P = .06) were
marginally signiﬁcantly diﬀerent between case and control
groups, occurring less frequently in the cases. Haplotype
TAC was the most common, with Hap-frequencies of
24.1%. Haplotype GGT was the most uncommon in CD
case (3.9%) and control (3.3%) subjects, but occurred
at equal frequencies in both (Hap-frequencies of 3.6%,
P > .05). Haplotypes GAC, GAT, and TGC occurred at
equal frequencies in CD patients and control subjects (P >
.05).
There were also signiﬁcant associations between these
haplotypes for UC cases as compared with control sub-
jects (χ2 = 46.3, df = 7, P < .0001). For the three
marker haplotypes (rs1061622, rs1061624, and rs3397),Gastroenterology Research and Practice 7
the frequencies of haplotypes of GGC (9.1% versus 3.1%,
P < .0001), TAC (17.9% versus 27.7%, P = .005), TAT
(17.0% versus 6.4%, P = .006), and TGT (11.2% versus
23.6%, P = .0007) were signiﬁcantly diﬀerent between
case and control subjects. Haplotype TAC was the most
common in UC cases (Hap-frequency of 27.8%, P = .005),
whereas haplotype GGT was the most uncommon in UC
patients and control subjects, with frequencies of 3.6% and
3.3%, respectively (Hap-frequency = 3.4%, P = .53). The
frequencies of GAC and TGC were lower and the frequency
of GAT higher in UC patients than control subjects, but
there was no statistically signiﬁcant diﬀerence between
them.
4. Discussion
The present results show that carrying a single variant allele
in TNFRSF1B c.676T > C, 1663A > G, or 1690T > Ch a s
no signiﬁcant eﬀect on the overall risk of either CD or
UC. However, the risk of certain phenotypes is aﬀected by
eitherofthelattertwovariantalleles.Morestriking,however,
is the eﬀect of carrying certain haplotypes, and speciﬁc
combinations may either increase or decrease the risk of
either CD or UC in the New Zealand Caucasian population,
with strong statistical signiﬁcance.
TNFRSF1B is the main TNF receptor found on circu-
lating T cells [14]. The gene contains 10 exons, spanning
around 26kb of genomic DNA and encoding 415 amino
acids [14]. Cysteine-rich extracellular regions, comprising
three to six disulﬁde-linked domains, are considered to be
important for ligand binding and are expressed by several
diﬀerent cell types [29]. The protein produced by the gene
forms a heterocomplex with the product of TNFRSF1A,
leading to recruitment of two antiapoptotic proteins c-
IAP1 and c-IAP2, both of which possess E3 ubiquitin
ligase activity. c-IAP1 has been suggested to potentiate
TNF-a induced apoptosis through the ubiquitination and
degradation of TNF-receptor-associated factor 2, which
produces antiapoptotic signals. We have previously shown
that TNF-alpha polymorphisms may contribute signiﬁ-
cantly to the risk of certain IBD phenotypes in the New
Zealand population [9]. The present data augment the
previous conclusion, that variant alleles associated with
this pathway are important for IBD risk in this popula-
tion.
There are limited data on the functionality of the
various SNPs in this gene. However, the 676 T > G
polymorphism replaces a methionine by an arginine, and
is functional, as the cytotoxic activity is increased [30].
The variant polymorphism has been previously associated
with susceptibility to familial rheumatoid arthritis (RA) [20]
and systemic lupus erythematosus (SLE) [21]. However,
association studies have suggested that the other SNPs
considered in the present study might be in linkage with a
functional SNP, even if not themselves functional [22, 23,
31]. Perhaps even more relevant to patients with IBD is
that associations have recently been demonstrated between
a two allele haplotypes and responses to IFB in Japanese CD
patients [28, 32].
Kawasaki et al. [31] reported no association between the
variant SNP at position 676 and the risk of either form of
IBD in their Japanese database. These data are consistent
with our own ﬁndings in the present study. However, these
data do not agree with other observations in a European
Caucasianpopulation[23]whichassociatedTNFRSF1Bwith
clinical CD phenotypes. They studied a well-phenotyped
cohort of 205 patients with CD and 106 controls to associate
the variant SNP at this position with increased risk of CD
(P = .034), but decreased risk with UC or with the need for
surgery. We suggest that the previous European consortium
data had insuﬃcient power to conclusively decide a negative
result.
It is of some interest that we have associated diﬀerences
in the risk of certain IBD phenotypes with variant alleles
in the other two SNPs considered (1663A > G, or 1690T >
C). A Japanese study considered 124 patients with CD, 106
patientswithUC,and111unrelatedhealthycontrols[22]for
these same two SNPs, while Waschke et al. [23] studied the
ﬁrst but not the second in their European Caucasian group.
Neither of these previous reports demonstrated a statistically
signiﬁcant diﬀerence in carrying either of the variant alleles.
We note, however, that in the Japanese population but not
in European groups [23], C appears to be the major allele at
position 1493.
Although Sashio et al. [22] reported only minor eﬀects
on IBD risk associated with carrying any single variant allele,
they found a signiﬁcant diﬀerence (odds ratio of 2.13) in
carrier frequency for haplotype AT (1466A, 1493T) between
CD patients and the controls. These diﬀerences were most
signiﬁcant in CD patients with either internal or external
ﬁstula,and/orwhorespondedpoorlytonutritional,medical,
or surgical therapy. Similar haplotype eﬀects are recorded in
the present study. However, we are currently unable to ﬁnd a
convincing explanation of the converse data for UC.
Although the region containing this gene has not
emerged from recent whole genome association studies as
a lead candidate in CD (WTCCC, 2007; Barrett et al.
2008) it is of interest that two of the genes consistently
appearing important are closely related to the present gene.
The protein product of TNFAIP3 (TNF-alpha- induced
protein 3) inhibits TNF-alpha-induced NFkB-dependent
gene expression by interfering with transactivation signals.
Markers with lower levels of signiﬁcance in these studies
include one within TNFSF15 (tumour necrosis factor super-
family, member 15). Taken together, the present data add
support to an important role for TNF-alpha and related
molecules in CD susceptibility and progression.
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